Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

LGVN

Longeveron Inc

Apr 19 • 04:00PM ET

1.92

Dollar change -0.09
Percentage change -4.48	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF IWC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-5.83	Insider Own	52.19%	Shs Outstand	1.03M	Perf Week	13.61%
Market Cap	6.24M	Forward P/E	-	EPS next Y	-22.20	Insider Trans	23.51%	Shs Float	0.98M	Perf Month	-46.87%
Income	-22.21M	PEG	-	EPS next Q	-2.15	Inst Own	7.75%	Short Float	2.86%	Perf Quarter	-79.79%
Sales	0.71M	P/S	8.79	EPS this Y	31.37%	Inst Trans	-	Short Ratio	0.01	Perf Half Y	-89.73%
Book/sh	2.72	P/B	0.70	EPS next Y	-217.14%	ROA	-107.90%	Short Interest	0.03M	Perf Year	-93.26%
Cash/sh	1.65	P/C	1.16	EPS next 5Y	-	ROE	-156.05%	52W Range	1.62 - 44.00	Perf YTD	-85.88%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-25.24%	ROI	-267.96%	52W High	-95.64%	Beta	0.46
Dividend TTM	-	Quick Ratio	1.50	Sales past 5Y	7.76%	Gross Margin	-102.12%	52W Low	18.52%	ATR (14)	0.74
Dividend Ex-Date	-	Current Ratio	1.50	EPS Y/Y TTM	-13.77%	Oper. Margin	-2966.01%	RSI (14)	37.19	Volatility	38.00% 29.93%
Employees	25	Debt/Eq	0.30	Sales Y/Y TTM	-41.98%	Profit Margin	-3132.72%	Recom	1.00	Target Price	30.05
Option/Short	No / Yes	LT Debt/Eq	0.21	EPS Q/Q	-1103.63%	Payout	-	Rel Volume	0.22	Prev Close	2.01
Sales Surprise	-70.00%	EPS Surprise	-17.19%	Sales Q/Q	-47.93%	Earnings	Feb 27 AMC	Avg Volume	2.05M	Price	1.92
SMA20	-29.78%	SMA50	-53.76%	SMA200	-88.75%	Trades		Volume	457,838	Change	-4.48%

Today 12:13PM	12 Cheap Foods With Anti-Aging Properties That Longevity Scientists Swear By (Insider Monkey)
Apr-18-24 04:05PM	Longeveron Raises a Total of $11.4 Million in Gross Proceeds from Warrant Exercise Offering and Public Offering (GlobeNewswire)
Apr-17-24 08:00AM	Longeveron Announces Exercise of Warrants for $6.2 Million Gross Proceeds (GlobeNewswire) -40.79%
Apr-16-24 01:08PM	Hedge Fund and Insider Trading News: Ken Griffin, Per Johansson, David Tepper, Michael Platt, Third Point LLC, Millennium Management, Bridgewater Associates, Paloma Partners, Longeveron Inc (LGVN), MongoDB, Inc. (MDB) and More (Insider Monkey) +20.48%
Apr-15-24 08:30AM	Longeveron's CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B in Mild Alzheimer's Disease Accepted for Featured Research Session Oral Presentation at the 2024 Alzheimer's Association International Conference (AAIC) (GlobeNewswire) +73.37%
08:24AM	Loading…
08:24AM	Why Is Longeveron (LGVN) Stock Up 48% Today? (InvestorPlace)
Apr-11-24 05:17PM	Longeveron Announces Closing of $5.2 Million Public Offering (GlobeNewswire) -10.22%
Apr-08-24 02:15PM	Longeveron Announces Pricing of $5.25 Million Public Offering (GlobeNewswire)
08:30AM	Longeveron Issues Letter to Shareholders Highlighting Corporate Strategy, Clinical Pipeline and 2024 Key Priorities and Goals (GlobeNewswire)
07:56AM	Why Is Longeveron (LGVN) Stock Up 82% Today? (InvestorPlace)
Mar-19-24 04:01PM	Longeveron Announces 1-for-10 Reverse Stock Split (GlobeNewswire)
Feb-28-24 10:05AM	With cash runways ending this year, Nicox and Longeveron trim staff and narrow focus (FierceBiotech.com) -5.95%
09:19AM	Longeveron Inc. (NASDAQ:LGVN) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-27-24 04:05PM	Longeveron Reports Year-End 2023 Results and Provides Corporate Update (GlobeNewswire) +7.19%
Feb-21-24 04:05PM	Longeveron to Report Year-End 2023 Results and Provide Corporate Update February 27, 2024 (GlobeNewswire)
08:00AM	Loading…
Jan-29-24 08:00AM	Longeveron Receives Notice of United States Patent Allowance for the Technology Behind its Lead Investigation Product Lomecel-B (GlobeNewswire) -16.07%
Dec-22-23 04:05PM	Longeveron Announces Closing of $2.36 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) +7.20%
Dec-21-23 10:34AM	UPDATE -- Longeveron Announces $2.36 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -22.84%
08:00AM	Longeveron Announces $2.36 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
Dec-20-23 08:00AM	Longeveron Announces Additional Positive Clinical Data and Imaging Biomarker Results from the CLEAR MIND Phase 2a Trial of Lomecel-B in the Treatment of Mild Alzheimer's Disease (GlobeNewswire) -16.92%
Nov-14-23 08:17AM	IBN Announces Latest Episode of The Bell2Bell Podcast featuring Wa'el Hashad, CEO of Longeveron Inc. (GlobeNewswire)
Nov-11-23 09:00AM	Long-term Survival Data from Longeveron's ELPIS 1 Trial Presented at the 2023 Scientific Sessions of the American Heart Association (GlobeNewswire)
08:38AM	Longeveron Inc. (NASDAQ:LGVN) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-10-23 07:30AM	Longeveron Reports Third Quarter 2023 Results and Provides Corporate Update (GlobeNewswire) -5.70%
Nov-03-23 08:00AM	Longeveron to Report Third Quarter 2023 Results and Provide Corporate Update on November 10, 2023 (GlobeNewswire)
Oct-24-23 08:30AM	Longeveron Inc. Featured in Syndicated Broadcast Highlighting Top-Line Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B for the Treatment of Mild Alzheimer's (GlobeNewswire)
Oct-13-23 04:05PM	Longeveron Announces Closing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
Oct-12-23 08:00AM	Longeveron Announces $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -9.24%
Oct-05-23 07:00AM	Longeveron Announces Positive Top-Line Results for Lomecel-B in its CLEAR MIND Phase 2a Clinical Trial in the Treatment of Mild Alzheimer's Disease (GlobeNewswire) -16.73%
Sep-12-23 09:00AM	Longeveron (NASDAQ: LGVN) Reports 100% 5-Year Survival In Trial For Rare Pediatric Disease HLHS (Compared To 80% Survival In Historical Trials) To Market (News Direct)
08:00AM	Loading…
Sep-11-23 08:00AM	Longeveron Issues Letter to Stockholders (GlobeNewswire)
Sep-07-23 08:30AM	IBN Coverage Initiated for Longeveron Inc. (GlobeNewswire)
08:00AM	Long-term Survival Data from Longeverons ELPIS 1 Trial Accepted for Presentation at the 2023 Scientific Sessions of the American Heart Association (GlobeNewswire)
Sep-05-23 08:00AM	Longeveron to Present at the 25th Annual H.C. Wainwright Global Investment Conference (GlobeNewswire)
07:00AM	Presenting on the Emerging Growth Conference on September 6 and 7 Register Now (GlobeNewswire)
Aug-29-23 08:00AM	Longeveron to Participate in the 149th Annual National Investment Banking Association Conference (GlobeNewswire)
Aug-22-23 08:00AM	Longeveron Rights Offering Subscription Period Begins (GlobeNewswire) +8.20%
Aug-16-23 09:13AM	Longeveron Rights Offering Declared Effective and Calendar Finalized (GlobeNewswire)
Aug-14-23 04:05PM	Longeveron to Host Key Opinion Leader Event on Medicinal Signaling Cells (MSCs) for Hypoplastic Left Heart Syndrome (HLHS) with Lomecel-B on August 16, 2023 (GlobeNewswire) -7.03%
08:00AM	Longeveron Announces Pricing for Rights Offering and Expected Calendar (GlobeNewswire)
Aug-11-23 07:30AM	Longeveron Reports Second Quarter 2023 Results and Provides Corporate Update (GlobeNewswire)
07:24AM	LGVN Makes Progress in Treatment for Devastating Diseases (Zacks Small Cap Research)
07:00AM	Longeveron Announces Achievement of Surpassing 50% Enrollment Threshold in Phase 2 ELPIS II Study of Lomecel-B in Hypoplastic Left Heart Syndrome (GlobeNewswire)
Aug-08-23 09:25AM	Longeveron Announces Key Additions To Its Leadership Team and Board As It Gears Up For Phase 2 Trials For Its Lead Drug Candidate For Several Conditions (News Direct)
07:00AM	Presenting on the Emerging Growth Conference on August 9 & 10 Register Now (GlobeNewswire)
Aug-07-23 08:00AM	Longeveron to Report Second Quarter 2023 Results and Provide Corporate Update on August 11, 2023 (GlobeNewswire)
Jul-20-23 08:00AM	Longeveron Appoints Lisa Locklear as Chief Financial Officer (GlobeNewswire)
Jul-11-23 08:00AM	Longeveron Appoints Dr. Nataliya Agafonova as Chief Medical Officer (GlobeNewswire)
Jul-10-23 08:00AM	Longeveron Congratulates Co-Founder and Chairman Dr. Joshua Hare on Induction as Fellow of National Academy of Inventors (GlobeNewswire)
Jul-07-23 09:00AM	HLHS Is A Rare And Serious Congenital Heart Disease With A 33% Neonatal Death Rate Could Longeverons Lomecel-B Improve Outcomes? (News Direct)
Jul-06-23 11:12AM	Will Longeveron (NASDAQ:LGVN) Spend Its Cash Wisely? (Simply Wall St.) -5.66%
Jun-27-23 06:07PM	Longeveron Files Registration Statement for Rights Offering (GlobeNewswire) -5.85%
Jun-13-23 08:30AM	Longeveron Welcomes Three New Prominent Board Members (GlobeNewswire)
May-12-23 08:32AM	LGVN Stock Earnings: Longeveron Misses EPS, Revenue Estimates (InvestorPlace)
08:20AM	LGVN: Announces Results and Progress on a Devastating Disease (Zacks Small Cap Research)
08:00AM	Longeveron Inc. Provides Corporate Update and Reports First Quarter 2023 Financial Results (GlobeNewswire)
May-09-23 05:23PM	Longeveron's Lomecel-BTM Shows Encouraging Survival Data, Keeps Hypoplastic Left Heart Syndrome Pediatric Patients Heart Transplant-Free (Benzinga) +26.58%
08:30AM	Longeveron Announces New Long-Term Survival Data from ELPIS I Trial of Lomecel-B for Hypoplastic Left Heart Syndrome (GlobeNewswire)
May-08-23 08:30AM	Longeveron to Announce First Quarter 2023 Financial Results on May 12, 2023 (GlobeNewswire)
Apr-19-23 08:59AM	Longeveron Announces First Patient Dosed in Phase 2 Clinical Trial of Lomecel-B for Aging-Related Frailty in Japan (GlobeNewswire)
Mar-14-23 02:38PM	Longeveron (NASDAQ:LGVN shareholders incur further losses as stock declines 18% this week, taking one-year losses to 51% (Simply Wall St.)
Mar-10-23 08:00AM	Longeveron Inc. Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire) -11.49%
06:10AM	LGVN: Longeveron Continues Progress Toward Important Treatments (Zacks Small Cap Research)
Mar-07-23 04:18PM	Insiders Just Bought $1 Million of This Deep Value Tech Stock (InvestorPlace)
Mar-06-23 08:30AM	Longeveron to Announce Fourth Quarter and Full Year Financial Results on March 10, 2023 (GlobeNewswire)
Feb-28-23 08:30AM	Longeveron Appoints Wael Hashad as Chief Executive Officer (GlobeNewswire)
Jan-27-23 08:51AM	Will Longeveron (NASDAQ:LGVN) Spend Its Cash Wisely? (Simply Wall St.)
Jan-19-23 08:35AM	LGVN: Longeveron Posts Positive Results for Life-Threatening Condition (Zacks Small Cap Research)
08:30AM	Longeveron Announces Publication of Final Data from ELPIS I Trial of Lomecel-BTM for Hypoplastic Left Heart Syndrome in Peer-Reviewed Journal (GlobeNewswire)
Jan-06-23 09:58AM	UPDATE -- Longeveron Provides Corporate Update and Announces 2023 Strategic Priorities and Anticipated Milestones (GlobeNewswire) +9.51%
08:30AM	Longeveron Provides Corporate Update and Announces 2023 Strategic Priorities and Anticipated Milestones (GlobeNewswire)
Nov-29-22 04:30PM	Longeveron to Participate in Upcoming 2022 Investor Conferences (GlobeNewswire) -9.18%
Nov-16-22 05:32AM	Longeveron Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS Lags (Simply Wall St.)
Nov-14-22 08:00AM	Longeveron Inc. Provides Corporate Update and Reports Third Quarter 2022 Financial Results (GlobeNewswire)
07:15AM	LGVN: Making Exciting Progress (Zacks Small Cap Research)
Nov-10-22 08:30AM	Longeveron Announces Completion of Enrollment in Phase 2a Trial of Lomecel-B for the Treatment of Alzheimers Disease (GlobeNewswire) +15.85%
Nov-07-22 09:06AM	Longeveron to Announce Third Quarter 2022 Financial Results on November 14, 2022 (GlobeNewswire)
Oct-05-22 02:34PM	Investing in Longeveron (NASDAQ:LGVN) a year ago would have delivered you a 13% gain (Simply Wall St.)
11:00AM	Insider Buying 2022: 15 Stocks to Bet On Despite the Bear Market (InvestorPlace)
08:30AM	Longeveron to Present at the Annual Dawson James Small Cap Growth Conference (GlobeNewswire)
Sep-15-22 08:30AM	Longeveron Names Jerome Bailey Vice President of Business Operations (GlobeNewswire)
Sep-06-22 08:30AM	Longeveron to Present at H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-31-22 08:30AM	U.S. Food and Drug Administration (FDA) Grants Fast Track Designation for Longeverons Lomecel-B Product for Treatment of Hypoplastic Left Heart Syndrome (HLHS) in Infants (GlobeNewswire) -7.80%
07:30AM	EXCLUSIVE: Longeveron's Lomecel-B Product Gets US FDA Fast Track Designation For Treatment Of Hypoplastic Left Heart Syndrome in Infants (Benzinga)
Aug-25-22 08:00AM	Longeveron Receives Intent to Grant Notice from the European Patent Office for Methods to Monitor Efficacy of Lomecel-B Cell Therapy Through Levels of Vascular Biomarker (GlobeNewswire)
07:30AM	EXCLUSIVE: Longeveron's Heart Disease Cell Therapy Poised To Secure European Patent (Benzinga)
Aug-20-22 08:45AM	We're Keeping An Eye On Longeveron's (NASDAQ:LGVN) Cash Burn Rate (Simply Wall St.)
Aug-12-22 08:00AM	Longeveron Inc. Provides Corporate Update and Reports Second Quarter 2022 Financial Results (GlobeNewswire)
07:36AM	LGVN: Quarterly Report Provides Good News (Zacks Small Cap Research)
Aug-08-22 08:30AM	Longeveron to Announce Second Quarter 2022 Financial Results on August 12, 2022 (GlobeNewswire)
Jul-27-22 09:33AM	LGVN: Alzheimers Study Gains Traction as CEO Search Continues (Zacks Small Cap Research)
Jul-07-22 08:00AM	Longeveron Announces Abstract Accepted for Presentation at the Alzheimers Association International Conference (AAIC) (GlobeNewswire) +21.18%
Jun-26-22 10:22AM	What Type Of Shareholders Make Up Longeveron Inc.'s (NASDAQ:LGVN) Share Registry? (Simply Wall St.)
May-21-22 10:16AM	Multiple insiders bought Longeveron Inc. (NASDAQ:LGVN) stock earlier this year, a positive sign for shareholders (Simply Wall St.)
May-13-22 08:00AM	Longeveron Inc. Provides Corporate Update and Reports First Quarter 2022 Financial Results (GlobeNewswire) +10.80%
07:12AM	LGVN: CEO Leaving but Progress Continues (Zacks Small Cap Research)
May-09-22 04:15PM	Longeveron Announces CEO Transition (GlobeNewswire)
08:30AM	Longeveron to Announce First Quarter 2022 Financial Results on May 13, 2022 (GlobeNewswire)
Apr-28-22 01:53PM	Investors in Longeveron (NASDAQ:LGVN) have made a favorable return of 78% over the past year (Simply Wall St.) -6.00%
Apr-14-22 08:58AM	Longeveron to Present at Longevity Leaders World Congress; Latinos and Alzheimers Symposium; International Frailty and Sarcopenia Research Conference (GlobeNewswire) +5.03%

Longeveron, Inc. is a clinical stage biotechnology company, which engages in the development of cellular therapies for specific aging-related and life-threatening conditions. Its lead product, LOMECEL-B, is a cell-based therapy product, which is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young, healthy, adult donors. The company was founded by Joshua M. Hare and Donald M. Soffer on October 9, 2014 and is headquartered in Miami, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hare Joshua	Chief Scientific Officer	Apr 11 '24	Buy	2.35	42,553	100,000	633,280	Apr 12 07:00 PM
Soffer Rock	Director	Apr 11 '24	Buy	2.35	31,915	75,000	208,534	Apr 12 07:00 PM
Hashad Mohamed Wa'el Ahmed	Chief Executive Officer	Apr 11 '24	Buy	2.35	10,638	24,999	19,616	Apr 12 07:00 PM
Soffer Rock	Director	Apr 10 '24	Buy	2.35	106,383	250,000	176,619	Apr 12 07:00 PM
Hare Joshua	Chief Scientific Officer	Apr 10 '24	Buy	2.35	106,383	250,000	590,727	Apr 12 07:00 PM
Ross Cathy	Director	Jan 10 '24	Buy	1.31	5,000	6,544	10,000	Jan 11 06:00 PM
Baluch Khoso	Director	Dec 29 '23	Buy	1.43	8,322	11,915	15,000	Jan 02 06:00 PM
PFEFFER JEFFREY	Director	Dec 28 '23	Buy	1.35	10,000	13,500	15,000	Dec 29 05:00 PM
Baluch Khoso	Director	Dec 28 '23	Buy	1.40	1,678	2,342	6,678	Jan 02 06:00 PM
Hare Joshua	Chief Scientific Officer	Sep 21 '23	Option Exercise	3.00	5,000	15,000	7,828,263	Sep 22 07:00 PM
Lehr Paul T	General Counsel, Secretary	Sep 20 '23	Option Exercise	3.00	2,000	6,000	144,213	Sep 21 05:00 PM
Hare Joshua	Chief Scientific Officer	Sep 12 '23	Option Exercise	3.00	30,000	90,000	7,823,263	Sep 14 05:09 PM
Hashad Mohamed Wa'el Ahmed	Chief Executive Officer	Sep 12 '23	Option Exercise	3.00	10,000	30,000	47,566	Sep 13 05:00 PM
Soffer Rock	Director	Sep 08 '23	Option Exercise	3.00	30,000	90,000	702,351	Sep 12 05:00 PM
Clavijo James	CFO and Treasurer	Jun 29 '23	Sale	3.51	5,000	17,550	47,303	Jun 29 05:00 PM
Clavijo James	CFO and Treasurer	Jun 28 '23	Sale	3.43	10,000	34,300	52,303	Jun 29 05:00 PM
Clavijo James	CFO and Treasurer	Jun 27 '23	Sale	3.48	8,532	29,691	62,303	Jun 29 05:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LGVN

Longeveron Inc

Upgrade your FINVIZ experience